Jeb Connor &
Adam Marsh, Ph.D.
Genome Profiling, LLC (GenPro) is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers based on its proprietary, genome-wide methylation profiling platform. Dr. Adam Marsh invented GenPro's underlying software technology while he was a faculty member in the Center for Bioinformatics and Computational Biology and the School of Marine Science and Policy at the University of Delaware. His primary research efforts focused on epigenetics of environmental imprinting in animals living in extreme environments (polar seas, deep oceans). His quantitative epigenetic profiling algorithm work started more than 10 years ago as an innovation of necessity to understand how invertebrate genomes thrived from generation to generation under the polar sea ice in Antarctica. Dr. Marsh is one of the earliest pioneers of computational epigenetics and currently serves as Chief Science Officer and Co-Founder of GenPro. Jeb Connor serves as Chairman, CEO and Co-Founder of GenPro. Mr. Connor's professional experience is grounded in 12 years of successful sales and senior management experience with Hewlett-Packard's Analytical Systems Group (now Agilent Technologies) where he was responsible for all aspects of their global lab automation systems business.
Rob Knight, Ph.D. &
Embriette Hyde, Ph.D.
The Knight Lab uses and develops state-of-the-art computational and experimental techniques to ask fundamental questions about the evolution of the composition of biomolecules, genomes, and communities in different ecosystems, including the complex microbial ecosystems of the human body. It subscribes to an open-access scientific model, providing free, open-source software tools and making all protocols and data publicly available in order to increase general interest in and understanding of microbial ecology and to further public involvement in scientific endeavors.
The goal of the American Gut Project, the world’s largest crowdfunded citizen science project, is to sequence as many as possible human microbiomes — the unique collection of bacteria and other microbes that live in and on us. Its participants are “citizen scientists.” It enables participants to learn about their own body’s microbes while also contributing to the greater scientific effort to learn how the human microbiome is associated with various aspects of our health-from associations with diet to the amount of alcohol someone drinks to whether or not someone has autism or IBD. Because all de-identified data are made freely available, researchers from all over the world can access the data to ask questions about the microbiome and its association with a variety of health and lifestyle factors. American Gut, British Gut, Australian Gut, and Asian Gut are part of the Earth Microbiome Project, a massive effort to analyze microbial communities across the globe. It is also a participant in the White House’s newly created National Microbiome Initiative. The American Gut Project was co-founded by Rob Knight, Ph.D., professor of pediatrics and computer science and engineering and Director of the Center for Microbiome Innovation at UC San Diego, and is currently managed by Embriette Hyde, Ph.D., an Assistant Project Scientist in the laboratory of Dr. Rob Knight at UC San Diego's School of Medicine.
Christopher Tompkins, Ph.D.
KromaTiD, Inc. provides products and services for mutation detection and disease diagnosis. KromaTiD’s patented Directional Genomic Hybridization™ (dGH™) chromosome imaging platform enables detection of all types of chromosomal rearrangements including previously undetectable cryptic inversions. KromaTiD’s research products and services are paving the way to a deeper understanding of genetic diseases, including cancers and developmental disorders. KromaTiD’s dGH™ technology combines bioinformatics driven design of unique single-stranded synthetic probes with strand-specific hybridization strategies, and is the only genomics approach capable of detecting DNA sequence, location and orientation in a single test. Assay design with dGH™ provides extremely strong signal strength, eliminates background, and detects small chromosomal rearrangements with high resolution.
Dr. Christopher Tompkins, serves as the President and General Manager of KromaTiD and is a member of the Board of Directors. He has twenty years of pharmaceutical and biotechnology industry experience focused in the areas of process development, operations and the commercialization of new technologies.
John Ryals, Ph.D., Lining Guo, Ph.D., & Bryan Whittmann, Ph.D
Metabolon’s platforms are powered by its proprietary software and dynamic biochemical reference library of more than 14,000 known and novel compounds. This big data technology allows Metabolon to rapidly and accurately identify and quantify metabolites while automatically filtering out extraneous data, such as data resulting from instrument noise. The result is clean, actionable metabolomics data that is ready for statistical analysis. Metabolomics improves our understanding of health and the influences of diet, drug treatment, genes and lifestyle. While genomics often reveals only predisposition or risk of disease, Metabolon provides a snapshot of the current state of health and actionable information to advance clinical decision-making and research.
Dr. John Ryals is president, CEO and a member of the Board of Directors. Dr. Lining Guo, Vice President, oversees the project management group at Metabolon for contract research and scientific collaboration with ~ 600 clients including leading pharmaceutical, biotech, consumer product/nutrition, agricultural companies, and academic institutions in the world. Dr. Bryan Whitman is Director of Precision Medicine at Metabolon.
Robin Smith & Marcie Glicksman, Ph.D.
ORIG3N is leading a transformation in the understanding and treatment of rare, genetically inherited diseases. Its science is based on Nobel Prize-winning regenerative medicine technology, and its approach will replace the trial-and-error guesswork of diagnosing and treating disease. ORIG3N has established the world’s largest uniformly consented cell repository to better understand the cellular and molecular foundations of disease. The cells are ever-renewing and give rise to a living database of humanity.
Robin Y. Smith serves as CEO, bringing over 20 years of startup, science, and entrepreneurial experience to ORIG3N. Dr. Marcie Glicksman has been in the drug discovery field for over 20 years. Before joining ORIG3N, she was Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN), part of the Harvard NeuroDiscovery Center. She holds a BA from Brown University and a Ph.D. in Neuroscience from Washington University.